You are viewing: Germany Biobanking Market analysis
Part of: Biobanking Market (Global)

The Germany Biobanking Market was valued at $541 Million in 2025 and projected to reach to $850.8 Million by 2030, representing a compound annual growth rate of 9.5%. Germany's biobanking market is positioned for sustained growth driven by increasing investments in precision medicine, genomic research, and personalized healthcare initiatives.

Germany Biobanking Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Germany Biobanking Market Trends and Insights

  • Germany's advanced healthcare infrastructure, strong regulatory framework, and significant investment in precision medicine are driving the adoption of biobanking solutions across research institutions and clinical facilities.
  • The country's leadership in biotechnology and pharmaceutical research positions Germany as a key hub for biobank development and sample management innovation. The German biobanking sector benefits from increasing demand for personalized medicine, growing prevalence of chronic diseases, and expanding genomic research initiatives.
  • Germany's commitment to data protection and ethical standards in biobanking creates a competitive advantage for market players.
  • Between 2025 and 2030, Germany is expected to see accelerated growth driven by technological advancements, increased collaboration between academic and commercial biobanks, and rising investment in translational research infrastructure..

Key Market Statistics

  • CAGR (2025-2030) 9.5% CAGR
  • Market Size, 2025 ~USD 541 Million
  • Forecast, 2030 ~USD 850.8 Million
  • Country Germany

Germany Biobanking Market Overview

Market Valuation & Growth :

Germany's biobanking market is valued at $541.0 million in 2025, with a projected CAGR of 9.5% through 2030, reaching $850.8 million. This growth outpaces the global average of 9.1%, reflecting strong domestic demand.

Healthcare Infrastructure Excellence :

Germany's advanced healthcare system, coupled with world-class research institutions and hospitals, provides an ideal ecosystem for biobanking adoption. The country's commitment to precision medicine and personalized healthcare drives continuous investment in biobanking infrastructure.

Regulatory Leadership :

Germany maintains a robust regulatory framework governing biobanking operations, ensuring compliance with EU standards and data protection regulations. This creates trust among healthcare providers and research institutions, accelerating market adoption.

Research & Innovation Hub :

Germany's leading pharmaceutical and biotechnology companies, combined with prestigious research centers, generate significant demand for biobanking solutions. The country's focus on translational research and clinical trials strengthens market expansion opportunities.

Germany Biobanking Market Dynamics

  • The country's strong pharmaceutical sector and academic research institutions continue to expand biobanking capabilities, supported by favorable regulatory conditions and EU funding programs.
  • Healthcare providers are increasingly adopting biobanking solutions to enhance clinical diagnostics and drug development pipelines. Looking ahead, Germany's biobanking market will benefit from technological advancements in sample processing, digital integration, and AI-driven analytics.
  • Growing collaborations between public research institutions and private biotech companies, combined with rising awareness of biobanking's role in disease prevention and treatment, will further accelerate market penetration across clinical and research settings through 2030..

Related Ecosystem

Biotechnology

Top Technologies
  • Reagents
  • Polymerase Chain Reaction (PCR)
  • Stem Cells
  • Assay Kits
  • Flow Cytometers
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.

    Key Takeaways

    • Germany's biobanking market is valued at $541.0 million in 2025 and is forecast to reach $850.8 million by 2030, representing a 9.5% CAGR.
    • Germany's advanced healthcare infrastructure and strong regulatory framework support the expansion of biobanking capabilities and precision medicine initiatives.
    • Increasing demand for personalized medicine and genomic research is driving biobank adoption across German research institutions and clinical facilities.
    • Germany's commitment to data protection and ethical standards positions the country as a trusted leader in biobanking innovation and sample management.

    Biobanking Market Report Scope

    Report Metric Details
    Base Year 2025
    Fastest Growing Segment SOFTWARE (Offering)
    Forecast Period 2025–2030
    Growth Rate CAGR of 9.1% from 2025 to 2030
    Largest Segment PRODUCTS (Offering)
    Market Size Base Year (Billions) ~USD 7.65 (2025)
    Revenue Forecast (Billions) ~USD 11.82 (2030)
    Segments Covered Offering, Type, Operation Type, Workflow, Sample Type, Ownership, Application, End User

    Germany Biobanking Market Report Segmentation

    8 segment dimensions are covered across the global market.

    By Offering

    • Products
    • Services
    • Software

    By Type

    • Alarm & Monitoring Systems
    • Clinical Research
    • Consumables
    • Cryogenic Storage Systems
    • Equipment
    • Freezers & Refrigerators
    • Life Science Research
    • Life Sciences Research
    • Other Equipment & Accessories
    • Other Services
    • Physical Biobanking Services
    • Temperature & Humidity Control Systems
    • Thawing Equipment
    • Virtual Biobanking Services

    By Operation Type

    • Automated Equipment
    • Automated Operations
    • Manual Equipment
    • Manual Operations

    By Workflow

    • Sample Analysis
    • Sample Collection & Storage
    • Sample Processing
    • Transport & Logistics

    By Sample Type

    • Biological Fluids
    • Blood Products
    • Human Waste Products
    • Nucleic Acids
    • Solid Tissues & Organs
    • Stem Cells & Cell Lines

    By Ownership

    • Academic & Research Institution Biobanks
    • Hybrid/Ppp Model
    • National/Regional Agencies
    • Other Ownership Models
    • Private/ Commercial Biobanks

    By Application

    • Diagnostic Applications
    • Other Applications
    • Research Applications
    • Therapeutic Applications

    By End User

    • Academic & Research Institutes
    • Biobanks
    • Cros
    • Hospitals & Diagnostic Laboratories
    • Pharma-Biotech Companies & Cros

    GERMANY: BIOBANKING SERVICES MARKET, BY END USER, 2023–2030

    Segment20232024202520262027202820292030CAGR (%)
    ACADEMIC & RESEARCH INSTITUTES34.235.438.542.346.751.657.163.410.5
    HOSPITALS & DIAGNOSTIC LABORATORIES21.32223.82628.631.534.738.410
    PHARMA-BIOTECH COMPANIES & CROS82.585.793.5102.9113.8126.1140.1155.910.8
    TOTAL138.1143155.8171.3189209.2231.9257.710.6

    GERMANY: BIOBANKING PRODUCTS MARKET, BY END USER, 2023–2030

    Segment20232024202520262027202820292030CAGR (%)
    BIOBANKS250.9258274.9296.2321.1349.5382419.28.8
    CROS72.47478.483.990.397.7106.1115.78.1
    TOTAL323.3332353.3380.1411.4447.3488.2534.98.7

    Target Audience

    • Biobanking Solution Providers : Companies offering biobanking software, equipment, and services need Germany-specific market data to identify growth opportunities, competitive positioning, and customer acquisition strategies in this high-value market.
    • Pharmaceutical & Biotech Companies : German and international pharma firms require detailed market intelligence to optimize biobanking investments, support clinical trial operations, and accelerate drug development pipelines in Germany.
    • Healthcare Institutions & Hospitals : German hospitals and research centers need market insights to justify biobanking infrastructure investments, benchmark against peers, and align with precision medicine initiatives.
    • Investment & Private Equity Firms : Investors evaluating biobanking opportunities in Germany require accurate market sizing, growth projections, and competitive analysis to make informed funding and acquisition decisions.
    • Government & Policy Makers : German healthcare authorities and research funding bodies use market data to develop biobanking policies, allocate research budgets, and support precision medicine infrastructure development.

    Key Companies in the Germany Biobanking Market

    CompanyHQOwnershipStrongest segments
    MAXCYTE, INCUnited StatesPublic CompanyExPERT ATx and STx instruments,ExPERT GTx and VLx instruments,Disposable processing assemblies (PAs),
    HDFC BANKIndiaPublic CompanyRetail Banking (deposits, consumer and home loans, cards),Wholesale Banking (corporate, SME, supply chain, trade),Treasury and Markets (money market, derivatives, investments),
    STANDARD CHARTEREDUnited KingdomPrivate CompanyFinancial Markets (FX, rates, commodities, credit),Transaction Banking (trade, cash, liquidity, custody),Corporate & Structured Finance,
    YES BANKIndiaPublic CompanyRetail banking (deposits, cards, consumer loans),Corporate and wholesale banking,MSME and business banking,
    CHOLAMANDALAM INVESTMENT AND FINANCE COMPANY LIMITEDIndiaPublic CompanyVehicle Finance (CV, PV, 2W/3W, tractors, construction equipment),Loan Against Property (LAP) and SME Secured Loans,Home Loans and Home Extensions,
    AXIS MUTUAL FUNDIndiaPrivate CompanyActively managed equity funds,Hybrid and asset allocation funds,Debt and money market funds,
    THERMO FISHER SCIENTIFIC INC.United StatesPublic CompanyLife Sciences Solutions,Analytical Instruments,Specialty Diagnostics,
    PHC HOLDINGS CORPORATIONJapanPublic CompanyDiabetes Management,Diagnostic and Life Sciences,Healthcare Solutions (EMR, billing, pharmacy, wellness),
    QIAGENNetherlandsPublic CompanySample technology consumables and instruments,Immune response and infectious disease diagnostics,Oncology and sexual & reproductive health assays,
    MERCK KGAAGermanyPublic CompanyLife Science (reagents, consumables, bioprocessing, CDMO/testing),Healthcare (prescription drugs and biopharmaceuticals),Electronics (semiconductor and display materials, specialty gases, equipment),
    AVANTOR, INC.United StatesPublic CompanyMaterials and consumables,Equipment and instrumentation,Services and specialty procurements,
    CRYOPORTUnited StatesPublic CompanyLife Sciences Services (logistics, biostorage, bioservices, consulting),Life Sciences Products (cryogenic freezers, dewars, accessories),IoT and digital monitoring solutions,
    AGILENT TECHNOLOGIES, INC.United StatesPublic CompanyLife Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets,
    LABCORPUnited StatesPublic CompanyRoutine and chronic-disease diagnostics (chemistry, hematology, A1C, thyroid, PSA, urinalysis),Specialty and esoteric testing (gene-based, oncology, cardiovascular, endocrinology, infectious disease),Biopharma Laboratory Services and clinical trial support,
    EUROFINS SCIENTIFICLuxembourgPublic CompanyFood and Feed Testing,Environment Testing,Biopharma and Clinical Diagnostics,
    HAIER BIOMEDICALChinaPublic CompanyULT freezers and low-temperature storage,Pharmacy and vaccine refrigerators/freezers, cold rooms,Blood bank and transfusion chain equipment,
    HAMILTON COMPANYUnited StatesPublic Investment FirmFund-of-funds (primary and secondary),Direct credit,Direct and co-investments / buyouts,

    MAXCYTE, INC

    MAXCYTE, INC is a public company based in the United States that was founded in 1998 and currently employs 91 people.

    HDFC BANK

    HDFC BANK is a public company based in India that was founded in 1994 and currently employs 212,958 people.

    STANDARD CHARTERED

    STANDARD CHARTERED is a private company based in the United Kingdom that was founded in 1853 and currently employs 66,524 people.

    YES BANK

    YES BANK is a public company based in India that was founded in 2003 and currently employs 29,577 people.

    CHOLAMANDALAM INVESTMENT AND FINANCE COMPANY LIMITED

    CHOLAMANDALAM INVESTMENT AND FINANCE COMPANY LIMITED is a public company based in India that was founded in 1978 and currently employs 51,320 people.

    AXIS MUTUAL FUND

    AXIS MUTUAL FUND is a private company based in India that was founded in 2009.

    THERMO FISHER SCIENTIFIC INC.

    THERMO FISHER SCIENTIFIC INC. is a public company based in the United States that was founded in 1956 and currently employs 125,000 people.

    PHC HOLDINGS CORPORATION

    PHC HOLDINGS CORPORATION is a public company based in Japan that was founded in 1948 and currently employs 8,647 people.

    QIAGEN

    QIAGEN is a public company based in the Netherlands that was founded in 1984 and currently employs 5,500 people.

    MERCK KGAA

    MERCK KGAA is a public company based in Germany that was founded in 1668 and currently employs 59,077 people.

    AVANTOR, INC.

    AVANTOR, INC. is a public company based in the United States that was founded in 1904 and currently employs 13,500 people.

    CRYOPORT

    CRYOPORT is a public company based in the United States that was founded in 1999 and currently employs 688 people.

    AGILENT TECHNOLOGIES, INC.

    AGILENT TECHNOLOGIES, INC. is a public company based in the United States that was founded in 1999 and currently employs 18,000 people.

    LABCORP

    LABCORP is a public company based in the United States that was founded in 1995 and currently employs 66,385 people.

    EUROFINS SCIENTIFIC

    EUROFINS SCIENTIFIC is a public company based in Luxembourg that was founded in 1987 and currently employs 65,694 people.

    HAIER BIOMEDICAL

    HAIER BIOMEDICAL is a public company based in China that was founded in 2005 and currently employs 2,945 people.

    HAMILTON COMPANY

    HAMILTON COMPANY is a public investment firm based in the United States that was founded in 1991 and currently employs 785 people.

    Reasons to Buy this Report

    • Market-Specific Sizing & Forecasts : Access precise valuation data for Germany's biobanking market with country-specific CAGR (9.5%) and detailed projections through 2030, enabling accurate business planning and investment decisions.
    • Competitive Landscape Intelligence : Understand Germany's unique competitive dynamics, key market players, and their strategies within the German biobanking ecosystem, distinct from broader European or global markets.
    • Regulatory & Compliance Insights : Gain detailed knowledge of Germany's specific regulatory framework, EU compliance requirements, and data protection standards that directly impact biobanking operations and market entry strategies.
    • Growth Driver Analysis : Identify Germany-specific growth catalysts including precision medicine adoption, pharmaceutical R&D investments, and clinical trial expansion that differentiate the German market opportunity.
    • Strategic Market Entry Planning : Develop targeted go-to-market strategies for Germany with insights into healthcare provider preferences, institutional partnerships, and regional demand patterns specific to the German market.

    Frequently asked questions

    What is the current size of Germany's biobanking market?

    Germany's biobanking market is valued at $541.0 million in 2025 and is expected to grow to $850.8 million by 2030.

    What is the projected growth rate for biobanking in Germany?

    Germany's biobanking market is projected to grow at a compound annual growth rate (CAGR) of 9.5% from 2025 to 2030.

    What factors are driving growth in Germany's biobanking market?

    Key drivers include increasing demand for personalized medicine, growing prevalence of chronic diseases, expanding genomic research initiatives, and rising investment in translational research infrastructure in Germany.

    How does Germany's regulatory environment support biobanking?

    Germany maintains a strong regulatory framework and commitment to data protection and ethical standards, which creates a competitive advantage for biobanking market players and supports innovation.

    What role does Germany play in the European biobanking market?

    Germany is a key hub for biobank development and sample management innovation in Europe, leveraging its advanced healthcare infrastructure and leadership in biotechnology and pharmaceutical research.

    RESEARCH METHODOLOGY

    This study involved four major activities to estimate the current size of the biobanking market. Exhaustive secondary research was conducted to gather information on the market, its peer markets, and its parent market. These findings, assumptions, and sizing were then validated with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the total market size. Following this, data triangulation was used to estimate the market size of segments and subsegments.

    Secondary Research

    Secondary research was primarily used to identify and gather information for the extensive, technical, market-oriented, and commercial study. Secondary sources for this study included publications from government sources, such as the European, Middle Eastern & African Society for Biopreservation and Biobanking (ESBB), Biobanking and BioMolecular Resources Research Infrastructure - European Research Infrastructure Consortium (BBMRI-ERIC), International Society for Biological and Environmental Repositories (ISBER), National Institutes of Health (NIH), and the US Food and Drug Administration (US FDA), as well as ScienceDirect and several others. Secondary sources also included corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements); business magazines and research journals; press releases; and trade, business, and professional associations. These sources were used to obtain key information on major players, global product revenues, market classification, and segmentation by industry trends, regional/country-level markets, market developments, and technology perspectives. Secondary data were collected and analyzed to determine the overall size of the global Biobanking market, and the findings were validated through primary research.

    Primary Research

    In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among others, to obtain and verify critical qualitative and quantitative information and to assess market prospects. Primary sources from both the supply and demand sides of the market were interviewed to gather qualitative and quantitative data. The following is a breakdown of the primary respondents:

    Biobanking Market Size, and Share

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    The global size of the biobanking market was estimated using multiple approaches. A detailed market estimation approach was used to estimate and validate the market value and other dependent submarkets. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

    Biobanking Market : Top-Down and Bottom-Up Approach

    Biobanking Market Top Down and Bottom Up Approach

    Data Triangulation

    After estimating the overall market size through the market size estimation process, the total market was divided into several segments. To complete the overall market engineering process and arrive at the exact statistics for all segments, the data triangulation procedure was employed; it involved analyzing various factors and trends from both the demand and supply sides.

    Market Definition

    Biobanking involves collecting, processing, storing, and managing biological samples—such as blood, tissues, stem cells, nucleic acids, and other human-derived materials—for research, diagnostic, and therapeutic applications. The market includes equipment, consumables, software, and services used by CROs, biobanks, pharmaceutical and biotechnology companies, and academic and research institutions. These entities manage diverse sample types, including blood products, human tissues, stem cells and cell lines, nucleic acids, biological fluids, and human waste products, using manual or automated systems depending on technological adoption. The market is also segmented by ownership models, including academic and research institutions, national and regional agencies, private organizations, and other entities.

    Key Stakeholders

    • Academic & Research Institutes
    • Biobanks
    • Contract Research Organizations (CROs)
    • Market Research and Consulting Firms
    • Pharmaceutical and Biotechnology Companies
    • Regulatory Agencies
    • Venture Capitalists
    • Forensics Labs
    • Government organizations
    • Private research firms
    • Hospitals and Diagnostic Laboratories

    Report Objectives

    • To define, describe, and forecast the biobanking market by offering, equipment-operation type, service-ownership, product-sample type, application, product-end user, service-end user, and region
    • To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
    • To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall biobanking market
    • To analyze opportunities for stakeholders and provide details of the competitive landscape for market leaders
    • To forecast the size of the market segments with respect to six regions: North America (US and Canada), Europe (Germany, France, the UK, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), Latin America (Brazil, Mexico, Argentina, and the Rest of Latin America), the Middle East [GCC Countries (Saudi Arabia (KSA), United Arab Emirates (UAE), and the Rest of GCC Countries) and the Rest of Middle East], and Africa
    • To profile the key players and analyze their market share and core competencies
    • To analyze competitive developments, such as product launches, partnerships, agreements, collaborations, and expansions
    • To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy

    Available customizations:

    With the given market data, MarketsandMarkets offers customization as per the company’s specific needs. The following options are available for the report:

    Geographical Analysis

    • Further breakdown of Rest of Europe biobanking market, by country
    • Further breakdown of Rest of Asia Pacific biobanking market, by country

    Comapany Information

    • Detailed analysis and profiling of additional market players (up to five)

    Segment Analysis

    • Cross-segment analysis

     

    Get the Full Biobanking Market Report

    Full forecast, segment splits, and company analysis for all Biobanking Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status